Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748291 | 0.86 | KDM4E (0.43) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL3164382 | 0.84 | AKR1C4 (0.43) | KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL11262018 | 0.84 | TDP1 (0.39) | KMT2AMEN1KDM4EALDH1A1MAOB | |
| SCHEMBL27703748 | 0.82 | KDM4E (0.52) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL14161554 | 0.82 | MEN1 (0.49) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL855752 | 0.78 | SMN1; SMN2 (0.50) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL219830 | 0.78 | HTR3A (0.50) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL857117 | 0.76 | ALDH1A1 (0.47) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14161482 | 0.74 | KDM4E (0.41) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL14161498 | 0.73 | MAOB (0.40) | KMT2AMEN1KDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604021-B2 | Substituted arylamine compounds and methods of treatment | BECKER OREN (IL) | 2013-12-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1856075-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | Epix Delaware, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | KMT2A 609/4885MEN1 3832/4885KDM4E 1616/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | KMT2A 609/4885MEN1 3832/4885KDM4E 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.